Tarik Asselah’s research while affiliated with Université Paris Cité and other places

... To accomplish this, expanded access, active HCV screening, and linkage to care are required. 4 Sofosbuvir-Velpatasvir (SOF-VEL) is a pangenotypic regimen coformulated with fixed-dose combinations of the nucleotide polymerase inhibitor sofosbuvir (400 mg) and the NS5A inhibitor velpatasvir (100 mg) for adult patients. The treatment with SOF-VEL for 12 weeks resulted in high rates of continuous absence of detectable HCV RNA for at least 12 weeks after the end of therapy (SVR12). ...

Reference:

Characteristics of a Chinese Cohort of Patients with Chronic Hepatitis C Infection (2019–2023) and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir Treatment

... Baseline HBsAg was a key determinant of treatment effects, as HBsAg seroclearance only occurred in patients with baseline HBsAg < 3 log IU/ml. [57] Elebsiran (siRNA) + Peg-IFNα has been studied in NUCtreated patients in phase II trials. Among 69 patients who received elebsiran (ranging from 6-13 doses) + Peg-IFNα (ranging from 12-48 doses), mean maximum HBsAg reduction by 1.7-3.0 ...

Reference:

Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies

... Consistent with prior studies, patients with CHD showed higher transaminases and advanced fibrosis compared to CHB, alongside a higher prevalence of HBeAg positivity [6,17,18]. Our novel finding of a more frequent and pronounced ALT elevation in young adults with CHD suggests a more active or prolonged phase of immune response targeting infected hepatocytes than previously known compared to HBV-monoinfection [19]. ...

Reference:

Prevalence and risk factors of elevated ALT in 3,399 treatment-naive HBV/HDV co-infected patients: A comparison with propensity score-matched HBV mono-infected patients

... Elevated alanine aminotransferase levels or laboratory-based scores such as FIB-4 ( brosis index score) or APRI (aspartate-platelets ratio index) might be more feasible to detect early liver diseases in healthy individuals, but cutoffs need further validation in populations with CHD. [32] On another aspect, our nding of increased prevalence of overweight and obesity among study participants, particularly in men might be considered for future screening of metabolic-related morbidities in this population. We believe that this screening included 10-20% of the Mongol population living in Sweden, however a selection favoring persons who use social media and having internet access (unknown the extent in this population) could not be ruled out. ...

Reference:

Prevalence of chronic viral hepatitis B, D among Mongol migrants in Sweden compared to a sex and age matched native Mongol cohort

... Among patients with qHBsAg < 1000 IU/mL, xalnesiran 200 mg + Peg-IFNα led to HBsAg seroclearance in 30% and 23% of patients at EOT and at 24 weeks post-EOT, respectively. In contrast, 18% and 12% of patients on xalnesiran 200 mg + ruzotolimod achieved HBsAg seroclearance at EOT and at 24 weeks post-EOT, respectively, whereas 3% of patients on xalnesiran 200 mg monotherapy achieved HBsAg seroclearance at both EOT and 24 weeks post-EOT [73]. The OCTOPUS-1 trial studied the use of daplusiran/ tomligisiran 200 mg for 24 weeks with nivolumab (antiprogrammed cell death 1). ...

Reference:

Investigational RNA Interference Agents for Hepatitis B

... BLV has been approved by regulatory agencies as a monotherapy, and the combination of BLV and Peg-IFN has not yet been clinically evaluated in large studies. The virological response of the combination in randomized clinical trials have been so far heterogeneous with rates of viral undetectability ranging from 44% in MYR204 19 to 60% in MYR203 20 after 48 weeks of treatments, but both of these results were obtained on a small number of patients. 21,22 In France, where off-label treatments can be reimbursed by the healthcare system, BLV can be used either alone or in combination with Peg-IFN, at the prescriber's discretion. ...

Reference:

Effect of Peg-IFN on the viral kinetics of HDV infected patients treated with bulevirtide

... The HBsAg levels remained at 1.70-1.85 log IU/ml below baseline at 24 weeks post-EOT, with 72-84% of patients remaining at HBsAg < 100 IU/ml at 24 weeks post-EOT [67]. ...

Reference:

Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies

... MYR 202 [38] MYR 204 [40] Objectif principal ARN VHD indétectable ou une diminution ≥ 2 log 10 ...

Reference:

Chimiothérapie des hépatites virales

... Le traitement par BLV est généralement bien toléré, et les effets indésirables observés lors des essais cliniques sont principalement bénins ou modérés. Des réactions au site d'injection sont courantes [41,42] . Une élévation des sels biliaires a été observée particulièrement chez les personnes avec une insuffisance rénale, sans retentissement clinique. ...

Reference:

Chimiothérapie des hépatites virales

... This variability in prevalence primarily stems from the absence of routine HDV screening and the lack of rapid diagnostic tests, which limits opportunities for early diagnosis [2]. In 2016, HBV infection prevalence in France was 0.3% [5], and HDV affected 3.5% of the population of people with HBV infection [6]. ...

Reference:

Unhealthy Behaviours and All‐Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta ( ANRS CO22 HEPATHER )